A locus for essential hypertension has been reported recently on chromosome 17 after sib-pair analysis with the use of microsatellite markers. 1, 2 The broad linkage region identified boarders, at cen-q11.2, the inducible nitric oxide (NO) synthase (iNOS) gene (NOS2A), which spans Ϸ37 kb and contains 26 exons, 3 exons 22 to 26 also being represented as 4 partially duplicated sequences in humans and great apes at this (NOS2B, ϪC) and other (ϪE) loci. 4 NOS2A, along with the neuronal (n) NOS and endothelial (e) NOS isoform genes, NOS1 and NOS3 (chromosomes 12q24.2-q24.31 and 7q35-q36), respectively, are involved in the generation of NO, a potent vasodilator. NOS2A is expressed in various tissues, including some relevant to the cardiovascular system, 5 viz, cardiac and vascular smooth muscle, renal tubules, and afferent arteriole. There is, moreover, evidence that intrarenal expression of iNOS can regulate arterial pressure. 6 Although NO is reduced in essential hypertension, 7 which may contribute to vascular and cardiac hypertrophy, 8 and NO markers correlate inversely with blood pressure, 7 there is no evidence to date that iNOS has a pathogenic role. In the spontaneously hypertensive rat (SHR), however, although iNOS expression is similar in vascular smooth muscle cells of prehypertensive rats and Wistar-Kyoto controls, 9 sustained NO production is lower in SHR, and NOS2 transcription differs between cells of each strain, leading to a suggestion that iNOS could be involved in the early rise in blood pressure. 9 Others have found abnormal expression later in SHR hypertension. 10 In Sabra DOCA salt-hypertensive rats, iNOS expression is reduced compared with their salt-resistant control strain, and greater NO generation could contribute to the salt resistance of the latter. 11 Dahl salt-sensitive hypertensive rats may have a defect in NO synthesis, seen in vivo 12 as well as in primary cultures of aortic smooth muscle cells, and a transversion, T2140C (Ser714Pro), has been noted in the iNOS gene of Dahl rats. 13 Moreover, various rat strains show a hypertension linkage region in the vicinity of Nos2. 14 -18 Two polymorphisms have been described for NOS2A. Both concern variation in repeated sequences and each is located in the 5Ј-flanking DNA. One is in an AAAT/AAAAT repeat at -756 to -716 relative to the major transcription start site (ϩ1) 19 and involves an insertion or deletion of 1 repeat unit. 20 The other, located 2.7 to 2.5 kb upstream, consists of 8 alleles of a CCTTT n pentanucleotide repeat with heterozygosity 0.80. 21 Of possible relevance to a disease such as hypertension, strand slippage in such repeats provides a rapid evolutionary mechanism for response to environmental change, with 9 to 16 repeat units in humans but only 3 to 9 in chimpanzees. 21 Similar sequences form a triplex structure in vivo, leading to S1 nuclease-sensitive sites that may affect gene regulation. 22 Poly-Pur/Pyr elements also occur in the 5Ј-flanking DNA of the ␤-globin 23 and rat AT1a angiotensin receptor 24 genes, and, as for NOS2A, 21 correspond to DNase I hypersensitive sites in active chromatin. Moreover, variation in repeat number in the insulin promoter affects promoter activity and onset of insulin-dependent diabetes mellitus (IDDM). 25 Using these polymorphisms of NOS2A as markers, we have conducted the first disease association and linkage studies of this gene. As well as examining hypertension itself, we also checked whether there was any effect on mortality in the same way as tested previously for angiotensin-converting enzyme (ACE) genotypes. 26 
Methods

Subjects
Association Study
The association study involved hypertensives with a strong genetic background (2 hypertensive parents). These have a greater likelihood of showing an existing association than for only 1 affected firstdegree relative 27 or an unselected hypertensive group. This group has, moreover, been the subject of a number of previous molecular genetic studies of hypertension, 28 -31 wherein ascertainment details have been described. In all there were 112 unrelated, age-and sex-matched, nondiabetic, treated white essential hypertensive patients and a control group of 164 normotensive subjects who also had parents who both had the same blood pressure status as theirs. Hypertensives with 2 affected parents represent Ϸ10% of all hypertensive patients. 26 Characteristics of the groups are shown in Table 1 . These studies had human ethics approval, and all subjects gave informed consent.
Sib-Pair Study
Two hundred thirty-four individuals from 98 hypertensive sibships (Ն2 affected sibs) were contacted by community advertising. All were Anglo-Caucasians, mainly from eastern Australia, principally Sydney, and had to have systolic/diastolic blood pressure of Ͼ140/ 90 mm Hg and not have diabetes or renal disease. After adjustment for 14 trios and 6 quartets, 32 the weighted sib-pair number was 156. Table 1 shows their characteristics.
Genotyping
DNA was isolated from whole blood by a modified salting-out method. 33 Genotypes for the biallelic polymorphism were determined by polymerase chain reaction (PCR) with the following primers: sense -5Ј-TGG TGC ATG CCT GTA GTC C-3Ј; antisense -5Ј-GAG GCC TCT GAG ATG TTG GTC-3Ј. The former was labeled with FAM during synthesis by Bresatec (Adelaide, South Australia). The PCR mix (25 L) consisted of 50 ng DNA, 20 nmol each primer, 0.25 mmol/L each dNTP, 1 U AmpliTaq Gold DNA polymerase (Perkin-Elmer), 50 mmol/L KCl, 10 mmol/L Tris-HCl, pH 8.3, 1.7 mmol/L MgCl 2 , and 4 g BSA. A "hot-start" protocol was used in which after initial denaturation at 94°C for 5 minutes, there were 10 cycles of 94°C, 65°C, and 72°C for 1 minute each, followed by 15 cycles of 94°C, 60°C, and 72°C for 1 minute each, and finally 20 cycles of 94°C, 58°C, and 72°C for 1 minute each, finishing with a step at 72°C for 30 minutes For the multiallelic marker, PCR primer sequences were: forward, 5Ј-ACC CCT GGA AGC CTA CAA CTG CAT-3Ј (FAM-labeled); reverse, 5Ј-GCC ACT GCA CCC TAG CCT GTC TCA-3Ј. The final PCR mix (8 L) was composed of 50 ng DNA, 5.4 nmol each primer, 0.24 mmol/L each dNTP, 0.4 U AmpliTaq Gold, 49 mmol/L KCl, 10 mmol/L Tris-HCl, pH 8.3, and 2 mmol/L MgCl 2 . After an initial denaturation step at 94°C for 12 minutes, 35 cycles of 94°C, 55°C, and 72°C for 30 seconds each were performed, finishing with a 10-minute step at 72°C.
All PCR products were electrophoresed on an ABI 377 automated sequencer (Applied Biosystems), and genotypes were assigned with ABI Genotyper software.
Statistical Analysis
Genotype data were used to calculate total alleles on all chromosomes, and these data were tested by 2 analysis with Excel 
Results
Biallelic Marker
Association Study Genotype and derived allele frequencies are shown in Table  2 . Hardy-Weinberg equilibrium was observed. 36 Frequency of the minor allele (ϩ) was 0.14 in the normotensive group and 0.18 in the hypertensive group. The difference was not significant. Minor allele frequency was 0.16 in male and 0.20 in female hypertensives (Pϭ0.5) and 0.18 in both lean (body mass index Ͻ26 kg/m 2 ) and obese (Ն26 kg/m 2 ) patients. Comparison by 1-way ANOVA of the various parameters in Table 1 across genotypes did not reveal any significant differences. For example, systolic blood pressure (meanϮSD, mm Hg) in the hypertensives was 174Ϯ25, 179Ϯ25, and 170Ϯ21 for -/-, ϩ/Ϫ, and ϩ/ϩ genotypes (nϭ62, 22 and 5), respectively, and for diastolic pressure was 112Ϯ17, 111Ϯ24, and 114Ϯ21. Values for plasma lipids, plasma renin, plasma angiotensinogen, and plasma ACE were similar to those described previously 26, 30 and did not differ between genotypes (data not shown).
Sib-Pair Study
Minor allele frequency in hypertensive sibs was 0.17. The biallelic marker was not very informative (information content ϭ 0.17). Linkage analysis of sib-pair data by SPLINK, either weighted or unweighted, gave Pϭ0.50, and analysis by APM produced Pϭ0.66. Thus each method showed no significant excess allele sharing.
Multillelic Marker
Association Study
Frequencies of the 8 alleles in each group are shown in Table  3 . Observed heterozygosity was 0.74 in the normotensive group, 0.81 in the hypertensive group, and 0.77 in the hypertensive sibs. Comparison of allele frequencies by 2 analysis showed no significant difference between the groups. Blood pressure and other parameters were also similar for each genotype.
The 2 markers were in weak linkage disequilibrium (DЈϭ 70%, Pϭ0.05) with alleles 193, 198, and 203 of the multiallelic marker begin associated with the ϩ allele of the biallelic marker, and alleles 178, 183, 188, 208, and 213 being associated with the Ϫ allele. 
Analysis in Different Age Groups
Genotype frequency is fixed from conception and should remain constant throughout life. Any deviation with age could indicate an effect on longevity. To test this, data in Table 2 were reanalyzed after subdivision into age groups of Ͻ50 years, 50 to 59, and Ն60, as done previously to reveal a deleterious effect of the deletion allele of an ACE gene variant in the same group. 26 As can be seen in Table 2 , although frequencies were virtually identical with control in the younger age groups, the older hypertensives had double the frequency of the "ϩ" allele (0.28), with correspondingly lower "Ϫ" allele frequency ( 2 ϭ7.4, Pϭ0.006). In contrast, the normotensives showed no difference with age (data not shown). Comparison of Ϫ/Ϫ with Ϫ/ϩ and ϩ/ϩ frequencies combined produced 2 ϭ7.9, Pϭ0.005. The hypertensive group but not the normotensives displayed, moreover, a significant interaction of age with genotype: -/-ϭ50.7Ϯ11.9 SD y (nϭ76), -/ϩϭ57.3Ϯ11.8 (nϭ27), and ϩ/ϩϭ53.8Ϯ13.3 (nϭ6) (Pϭ0.05 by ANOVA). Pretreatment blood pressures were similar for each genotype, in each age group; for example, in the older subgroup, systolicϭ183Ϯ24 SD, 182Ϯ20, 180Ϯ14 for -/-, -/ϩ, and ϩ/ϩ (nϭ16, 20, and 2, respectively); diastolicϭ112Ϯ15, 112Ϯ23, 113Ϯ4. All parameters were similar for older versus younger patients, except that pretreatment systolic pressure was higher in the older subgroup (182Ϯ21 vs 171Ϯ26 SD mm Hg; Pϭ0.03).
Similar analyses in the hypertensive sibs, whose blood pressure was lower overall (mean diastolicϭ103 vs 112 mm Hg; Table 1 ), showed no difference across age groups ("Ϫ" frequency: 0.15, 0.20, 0.16 for age Ͻ50, 50 to 59, and Ն60 years, respectively). However, restriction to sibs with more severe hypertension (diastolic Ն100 mm Hg; meanϭ107Ϯ10 SD) revealed a genotypic difference in the 20 sibs Ն60 years: viz, 0.60, 0.40, and 0.0 for -/-, -/ϩ, and ϩ/ϩ, respectively (Pϭ0.03 vs normotensives). For the 38 sibs Ͻ60 years of age (with diastolic Ն100 mm Hg), genotype values (0.76, 0.21, and 0.03) for -/-, -/ϩ, and ϩ/ϩ were similar to the normotensives. Age for each genotype of the more severely hypertensive sibs was 57Ϯ10 (SD) years, 59Ϯ10, and 57, respectively (nϭ48, 20, and 1).
For the multiallelic marker, although numbers for each allele were smaller, no age-related differences could be seen (data not shown).
Discussion
The present study found no evidence for association or linkage of markers at the NOS2A locus with essential hypertension. We tested both biallelic and multiallelic polymorphisms. The former are preferred in association studies, whereas the latter can provide the necessary informativeness for linkage analyses. Association studies test whether a disease and an allele show correlated occurrence in a population, whereas linkage studies test whether they show a correlated transmission within a pedigree. 37 Biallelic allele frequency in our normotensives and younger hypertensives was similar to what others have observed in unselected European whites (minor allele frequencyϭ0.15, nϭ35). 20 Since, in the absence of exhaustive studies, it is generally believed that results of association analyses only apply to the polymorphism tested, the present findings do not rule out hypertension association for (an)other variant(s) in or near NOS2A that is not in linkage disequilibrium with the markers tested.
The negative sib-pair linkage result suggests either that the NOS2A locus is not linked to essential hypertension or the size of the study group was insufficient to provide sufficient power to reveal a small genetic contribution of NOS2A or a linked gene to hypertension. For strong family history and disease onset before age 55 years, relative risk to a sibling ( s ) is 3.8, 38 meaning that in a complex disease Ϸ100 sib-pairs would be sufficient to provide 90% power to show significant linkage at the Lod Ն3 (PՅ0.0001 39 ) level. 40 For a disease with multiple weak contributing loci (eg, s values of Ϸ2), 156 sibs should have 90% power to provide evidence at the Lod Ն2 (PՅ0.001) level, 40 as indeed we have found with our number of sibs for markers on chromosome 17 2 and as others have reported for the angiotensinogen locus. 41 Thus a negative result from both association and linkage analysis helps provide some assurance about the validity of the conclusion reached but does not completely rule out a contribution to the disease tested.
Our 2 groups of hypertensives had similar inclusion criteria and geographic location. However, the stronger family history of hypertensives with 2 hypertensive parents may explain why their age of onset of hypertension (32Ϯ10 [SD] years) was earlier than the hypertensive sibs (43Ϯ13 years), so accounting for their lower age (53Ϯ12 [SD] vs 61Ϯ10 years) and more severe hypertension (Table 1) . Moreover, the fact that age of onset for the older hypertensives (33Ϯ7 years) was similar to the younger hypertensives rules out a different pathogenesis involving late-onset disease.
There has been no previous molecular genetic study of NOS2A in hypertension, so our results add to findings for NOS1, in which an 8-allele microsatellite (heterozygosity 0.52) in exon 29 failed to show association with hypertension in Japanese patients, 42 and NOS3, in which a 24-allele dinucleotide repeat (polymorphism information content 0.92) in intron 13 showed no linkage with hypertension in 269 white sib-pairs 43 nor association in 88 hypertensives with 2 hypertensive parents. 44 In Japanese patients, although no difference was observed for the whole group, hypertensives without left ventricular hypertrophy showed a weak (Pϭ0.02) association with hypertension. 45 Two other single-base substitution polymorphisms, in introns 18 and 23, have also proved negative for hypertension in whites, 43, 46 but a T/G variant in exon 7 that causes an amino acid substitution (Asp298Glu) was 16% more frequent (Pϭ0.004). 46 It displayed, however, no association with blood pressure. 46 Thus results to date for NOS1 and NOS3 also provide little support for each in the pathogenesis of hypertension.
Although we found no association in the group as a whole or in younger hypertensives, in the case of the biallelic variant, older more severely affected hypertensives of either group displayed a 2-fold elevation in ϩ/Ϫ-genotype frequency and a one-third reduction in -/-genotype frequency. -/ϩ hypertensives were also 7 years older than -/-hypertensives. No conclusion could be made about ϩ/ϩ homozygotes because patient number and population frequency for this genotype was low.
A possible cause of altered genotype frequency with age may involve effects on survival or mortality. Our results would be consistent with a deleterious effect in high-risk patients with the -/-genotype or a survival advantage in those with the -/ϩ genotype. What this would mean is that at the level of the gene, the promoter variant tested could affect NOS2A expression or be in linkage disequilibrium with (an)other variant(s) that confers altered promoter activity, mRNA stability, or is a sequence variant of iNOS having different enzymatic activity. Thus alteration in iNOSmediated NO formation could affect death rate in at-risk individuals.
Depending on the tissue, cytotoxic effects of elevated iNOS activity might be either beneficial, for example, in reducing tumor growth, 47 or harmful, for example, in ␤-cell destruction and onset of non-insulin-dependent diabetes mellitus (NIDDM), 48 atherosclerosis, 49 and coronary disease. 50 Infections result in an iNOS response, which may be beneficial or deleterious, depending on the pathogen. 47 Survival effects could involve its immune or proinflammatory functions, 47 and enhanced vasodilatory actions could be cardioprotective. The effects of iNOS therefore appear dichotomous. 47 However, the greatest cause of death in patients Ͼ60 years of age with moderate to severe hypertension is heart attack and stroke. 51 Atherosclerosis is an exacerbatory factor, for which iNOS has both pathogenic 49 and protective 52 functions. Both iNOS and ACE are elevated markedly in human coronary plaque macrophages. 53 Higher iNOS levels in Ϫ/Ϫ patients could thus have a survival disadvantage.
If our results do indeed reflect an effect on longevity, the rarity of the ϩ allele makes it difficult to say whether the ϩ allele might be genetically dominant, that is, whether it has a similar effect in -/ϩ and ϩ/ϩ patients or whether heterozygosity provides a greater relative survival advantage than either allele alone.
In conclusion, the present work provides no support for involvement of the iNOS gene (NOS2A) in the genetics of essential hypertension but suggests that genetic variation involving a tetranucleotide repeat in the promoter is associated with mortality.
